Rachel M. Squillace

2.1k citations

21 papers · 1.4k indexed · h-index 20

Molecular Biology top 10%
Physiology top 10%
Pulmonary and Respiratory Medicine top 10%
Oncology top 10%
Cancer Research top 10%

Co-authors: David J. Kwiatkowski Shulin Wu Jingxiang Huang Katrin Düvel Chin‐Lee Wu Brendan D. Manning Huihui Zhang Cheryl A. Doughty
Topics: PI3K/AKT/mTOR signaling in cancer (8 papers)Tuberous Sclerosis Complex Research (4 papers)Lung Cancer Treatments and Mutations (3 papers)
Cited by: Aging Molecular Biology Cancer Research
Journals: Journal of Biological Chemistry Journal of Clinical Investigation Molecular Cell
Partner nations: United States Netherlands Japan

In The Last Decade

Rachel M. Squillace

21 papers receiving 1.4k citations

Peers

Countries citing papers authored by Rachel M. Squillace

Since Specialization

Citations

This map shows the geographic impact of Rachel M. Squillace's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Rachel M. Squillace with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Rachel M. Squillace more than expected).

Fields of papers citing papers by Rachel M. Squillace

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Rachel M. Squillace. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Rachel M. Squillace. The network helps show where Rachel M. Squillace may publish in the future.

Co-authorship network of co-authors of Rachel M. Squillace

This figure shows the co-authorship network connecting the top 25 collaborators of Rachel M. Squillace. A scholar is included among the top collaborators of Rachel M. Squillace based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Rachel M. Squillace. Rachel M. Squillace is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	A novel acquired ALK F1245C mutation confers resistance to crizotinib in ALK-positive NSCLC but is sensitive to ceritinib 2015 ·Lung Cancer ·(unknown),Julia A. Elvin,Rachel M. Squillace,(unknown),Vincent A. Miller,Siraj M. Ali,Samuel J. Klempner,Sai‐Hong Ignatius Ou	24
2	Characterization of Clinical Cases of Collecting Duct Carcinoma of the Kidney Assessed by Comprehensive Genomic Profiling 2015 ·European Urology ·Sumanta K. Pal,Toni K. Choueiri,Kai Wang,Depinder Khaira,José A. Karam,Eliezer M. Van Allen,Norma Alonzo Palma,Mark N. Stein,Adrienne Johnson,Rachel M. Squillace,Julia A. Elvin,Juliann Chmielecki,Roman Yelensky,Evgeny Yakirevich,Doron Lipson,Douglas I. Lin,Vincent A. Miller,Philip J. Stephens,Siraj M. Ali,Jeffrey S. Ross	87
3	Novel Small Molecule Inhibitors of Choline Kinase Identified by Fragment-Based Drug Discovery 2015 ·Journal of Medicinal Chemistry ·Stephan G. Zech,Anna Kohlmann,Tianjun Zhou,Feng Li,Rachel M. Squillace,(unknown),Matthew T. Greenfield,David P. Miller,Jiwei Qi,Renjith Thomas,Yihan Wang,Yongjin Xu,Juan J. Miret,William C. Shakespeare,Xiaotian Zhu,David C. Dalgarno	34
4	A Multicenter, First-in-Pediatrics, Phase 1, Pharmacokinetic and Pharmacodynamic Study of Ridaforolimus in Patients with Refractory Solid Tumors 2013 ·Clinical Cancer Research ·Lia Gore,Tanya Trippett,Howard M. Katzenstein,Jessica Boklan,Aru Narendran,Amy Smith,Margaret E. Macy,(unknown),(unknown),Rachel M. Squillace,Christopher Turner,Frank G. Haluska,Michael L. Nieder	19
5	Combined targeting of FGFR2 and mTOR by ponatinib and ridaforolimus results in synergistic antitumor activity in FGFR2 mutant endometrial cancer models 2013 ·Cancer Chemotherapy and Pharmacology ·Joseph M. Gozgit,Rachel M. Squillace,Matthew Wongchenko,David F. Miller,Scott Wardwell,Qurish K. Mohemmad,Narayana I. Narasimhan,Frank Wang,Tim Clackson,Victor M. Rivera	50
6	Abstract 5655: AP26113 possesses pan-inhibitory activity versus crizotinib-resistant ALK mutants and oncogenic ROS1 fusions. 2013 ·Cancer Research ·Rachel M. Squillace,Rana Anjum,David F. Miller,Sadanand Vodala,Lauren Moran,Frank Wang,Tim Clackson,Andrew P. Garner,Victor M. Rivera	31
7	Synergistic activity of the mTOR inhibitor ridaforolimus and the antiandrogen bicalutamide in prostate cancer models 2012 ·International Journal of Oncology ·Rachel M. Squillace,David F. Miller,Scott Wardwell,Frank Wang,Tim Clackson,Victor M. Rivera	27
8	Redox Proteomics Analyses of the Influence of Co-Expression of Wild-Type or Mutated LRRK2 and Tau on C. elegans Protein Expression and Oxidative Modification: Relevance to Parkinson Disease 2012 ·Antioxidants and Redox Signaling ·Fabio Di Domenico,Rukhsana Sultana,Andrew Ferree,(unknown),Eugenio Barone,Marzia Perluigi,Raffaella Coccia,William M. Pierce,Jian Cai,Cesare Mancuso,Rachel M. Squillace,(unknown),Isabella Dalle‐Donne,Benjamin Wolozin,D. Allan Butterfield	46
9	Abstract 1794: AP26113 is a dual ALK/EGFR inhibitor: Characterization against EGFR T790M in cell and mouse models of NSCLC 2012 ·Cancer Research ·Victor M. Rivera,Frank Wang,Rana Anjum,Sen Zhang,Rachel M. Squillace,Jeffrey Keats,David F. Miller,Yaoyu Ning,Scott Wardwell,Lauren Moran,Juan J. Miret,Narayana I. Narasimhan,David C. Dalgarno,Tim Clackson,(unknown)	36
10	Antitumor Activity of Ridaforolimus and Potential Cell-Cycle Determinants of Sensitivity in Sarcoma and Endometrial Cancer Models 2011 ·Molecular Cancer Therapeutics ·Rachel M. Squillace,David F. Miller,(unknown),Scott Wardwell,Lauren Moran,David E. Clapham,Frank Wang,Tim Clackson,Victor M. Rivera	40
11	Ridaforolimus (AP23573; MK-8669), a Potent mTOR Inhibitor, Has Broad Antitumor Activity and Can Be Optimally Administered Using Intermittent Dosing Regimens 2011 ·Molecular Cancer Therapeutics ·Victor M. Rivera,Rachel M. Squillace,David F. Miller,Lori Berk,Scott Wardwell,Yaoyu Ning,Roy M. Pollock,Narayana I. Narasimhan,John D. Iuliucci,Frank Wang,Tim Clackson	87
12	Regulation of Physiologic Actions of LRRK2: Focus on Autophagy 2011 ·Neurodegenerative Diseases ·Andrew Ferree,Maria Guillily,Hu Li,(unknown),(unknown),Rachel M. Squillace,Manfred Weigele,James J. Collins,Benjamin Wolozin	34
13	The evolutionarily conserved TSC/Rheb pathway activates Notch in tuberous sclerosis complex and Drosophila external sensory organ development 2010 ·Journal of Clinical Investigation ·Magdalena Karbowniczek,(unknown),Damir Khabibullin,Tiffiney R. Hartman,Jane Yu,Tasha Morrison,Émmanuelle Nicolas,Rachel M. Squillace,Fabrice Roegiers,Elizabeth P. Henske	50
14	Insulin Stimulates Adipogenesis through the Akt-TSC2-mTORC1 Pathway 2009 ·PLoS ONE ·Huihui Zhang,Jingxiang Huang,Katrin Düvel,(unknown),Shulin Wu,Rachel M. Squillace,Chin‐Lee Wu,Brendan D. Manning	315
15	Rapamycin-Insensitive Up-Regulation of MMP2 and Other Genes in Tuberous Sclerosis Complex 2–Deficient Lymphangioleiomyomatosis-Like Cells 2009 ·American Journal of Respiratory Cell and Molecular Biology ·Po‐Shun Lee,(unknown),Marsha A. Moses,(unknown),Li‐Li Hsiao,Roderick V. Jensen,Rachel M. Squillace,David J. Kwiatkowski	47
16	Anti-proliferative activity of the mTOR inhibitor deforolimus (AP23573; MK-8669) in combination with cytotoxic and targeted agents in sarcoma and endometrial cancer models 2008 ·Cancer Research ·Rachel M. Squillace,David F. Miller,Tim Clackson,Victor M. Rivera	1
17	mTOR-Raptor Binds and Activates SGK1 to Regulate p27 Phosphorylation 2008 ·Molecular Cell ·Feng Hong,Michelle D. Larrea,Cheryl A. Doughty,David J. Kwiatkowski,Rachel M. Squillace,Joyce M. Slingerland	210
18	Expression pattern of muscleblind-like proteins differs in differentiating myoblasts 2007 ·Biochemical and Biophysical Research Communications ·(unknown),Rachel M. Squillace,Edith H. Wang	19
19	Inhibition of Muscle Differentiation by the Novel Muscleblind-Related Protein CHCR 2002 ·Developmental Biology ·Rachel M. Squillace,(unknown),Edith H. Wang	53
20	α7 Integrin Mediates Cell Adhesion and Migration on Specific Laminin Isoforms 1996 ·Journal of Biological Chemistry ·Chung‐Chen Jane Yao,Barry L. Ziober,Rachel M. Squillace,Randall H. Kramer	96

About Rachel M. Squillace

Rachel M. Squillace is a scholar working on Oncology, Physiology and Cancer Research, having authored 21 papers that have together received 1.4k indexed citations. Recurring topics across this work include PI3K/AKT/mTOR signaling in cancer (8 papers), Tuberous Sclerosis Complex Research (4 papers) and Lung Cancer Treatments and Mutations (3 papers). The work is most often cited by research in Aging (24 citations), Molecular Biology (907 citations) and Cancer Research (174 citations). Rachel M. Squillace has collaborated with scholars based in United States, Netherlands and Japan. Frequent co-authors include David J. Kwiatkowski, Shulin Wu, Jingxiang Huang, Katrin Düvel, Chin‐Lee Wu, Brendan D. Manning, Huihui Zhang, Cheryl A. Doughty, Joyce M. Slingerland and Feng Hong. Their work appears in journals such as Journal of Biological Chemistry, Journal of Clinical Investigation and Molecular Cell.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact